KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Change in Cash (2016 - 2025)

Globus Medical (GMED) has disclosed Change in Cash for 15 consecutive years, with $154.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 4.51% year-over-year to $154.4 million, compared with a TTM value of -$258.3 million through Dec 2025, down 181.44%, and an annual FY2025 reading of -$258.3 million, down 181.44% over the prior year.
  • Change in Cash was $154.4 million for Q4 2025 at Globus Medical, up from $142.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $212.3 million in Q3 2024 and bottomed at -$323.2 million in Q1 2025.
  • Average Change in Cash over 5 years is $14.3 million, with a median of $46.5 million recorded in 2022.
  • Peak annual rise in Change in Cash hit 7165.24% in 2021, while the deepest fall reached 1405.86% in 2021.
  • Year by year, Change in Cash stood at -$168.8 million in 2021, then soared by 109.62% to $16.2 million in 2022, then soared by 1055.4% to $187.7 million in 2023, then fell by 13.85% to $161.7 million in 2024, then decreased by 4.51% to $154.4 million in 2025.
  • Business Quant data shows Change in Cash for GMED at $154.4 million in Q4 2025, $142.3 million in Q3 2025, and -$231.8 million in Q2 2025.